Lifecore Biomedical

LFCR

Market cap $293M

Philadelphia, Pennsylvania--(Newsfile Corp. - January 13, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR) as a securities fraud class action has reached a settlement. The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

Philadelphia, Pennsylvania--(Newsfile Corp. - January 8, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR) The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company. Current Lifecore Biomedical, Inc. (NASDAQ: LFCR) who have held shares since before October 7, 2020, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever.

Lifecore Biomedical (LFCR) has completed its turnaround, emerging as a pure-play US-based CDMO with a cleaned-up balance sheet and high operational leverage. LFCR's new capacity is underutilized but already contracted, with management guiding revenues to rise from $128M to $178–205M and EBITDA margins to expand from 15% to over 25%. Alcon's take-or-pay contract and a major commercial site transfer underpin the revenue ramp, while macro tailwinds and supply chain onshoring boost demand.

Philadelphia, Pennsylvania--(Newsfile Corp. - December 30, 2025) - Grabar Law Office is investigating claims on behalf of shareholders of Lifecore Biomedical, Inc. (NASDAQ: LFCR) The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company. Current Lifecore Biomedical, Inc. (NASDAQ: LFCR) who have held shares since before October 7, 2020 can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever.

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.   NEW YORK , Dec. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Lifecore Biomedical, Inc. (NASDAQ: LFCR) breached their fiduciary duties to shareholders.

CHASKA, Minn., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has been notified by Nasdaq that the company's stock is expected to be added to the Nasdaq Biotech Index (NASDAQ: NBI) as part of the annual reconstitution of the 2025 Nasdaq indexes. Lifecore's inclusion in the Nasdaq Biotech Index will be effective prior to market open on Monday, December 22, 2025.

Agreement Calls for Development Services and Tech Transfer in Preparation for Commercial Manufacturing of Injectable Pharmaceutical Product

CHASKA, Minn., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 44th Annual J.P.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Lifecore Biomedical, Inc. (NASDAQ: LFCR) breached their fiduciary duties to shareholders. If you currently own Lifecore stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about.

CHASKA, Minn, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in two upcoming investor conferences. Details regarding Lifecore's participation are as follows: